Results look outstanding to me. Excellent performance in all product areas and geographical regions, all underpinned by strong R&D. Seqirus seems to be running according to management predictions. I was interested to see (p.9 of report) that they are proceeding to Phase 3 study for CSL 112 (product to reduce cholesterol). That must have been a significant decision, since I presume that Phase 3 studies are expensive.
Ann: Half Year Results Analyst Presentation, page-7
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$277.01 |
Change
-7.040(2.48%) |
Mkt cap ! $134.1B | |||
| Open | High | Low | Value | Volume |
| $280.67 | $281.07 | $275.01 | $254.8M | 915.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 1140 | $277.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $277.08 | 312 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |